Alexander Coltoff1, Ruben Mesa2, Jason Gotlib3, Jessica Shulman4, Raajit K Rampal4, Olivia Siwoski5, Abdulraheem Yacoub5, Alison Moliterno6, Anna Yang6, Evan Braunstein6, Aaron T Gerds7, Gabriela S Hobbs8, Elliott F Winton9, Swati Goel10, Martha Wadleigh11, Douglas Tremblay12, Erin Moshier12, John Mascarenhas13. 1. Department of Hematology/Oncology, Columbia New York Presbyterian, New York, NY. 2. Mays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, TX. 3. Department of Medicine, Division of Hematology, Cancer Institute, Stanford University, Stanford, CA. 4. Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS. 6. Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 7. Leukemia and Myeloid Disorders Program, Cleveland Clinic, Cleveland, OH. 8. Cancer Center, Massachusetts General Hospital Harvard Medical School, Boston, MA. 9. Winship Cancer Institute, Emory University, Atlanta, GA. 10. Division of Hematology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. 11. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 12. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. 13. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu.
Abstract
INTRODUCTION: Ruxolitinib is approved for the treatment of polycythemia vera (PV) with hydroxyurea resistance or intolerance. Approval was based on the phase III RESPONSE trial, which demonstrated efficacy in a highly selected patient population. MATERIALS AND METHODS: To characterize the tolerability and outcomes of ruxolitinib outside of a clinical trial, we performed a multi-center retrospective analysis of patients with PV treated with ruxolitinib at 11 participating sites across the United States. Outcomes of interest included change in phlebotomy requirements after starting ruxolitinib and spleen response, as these were included in the primary composite outcome in the RESPONSE trial. RESULTS: One hundred twenty-six patients met eligibility criteria, and the median duration of follow-up was 22.4 months (range, 0-63.0 months). At 32 weeks after starting ruxolitinib, the percentage of patients who received at least 1 phlebotomy was significantly decreased compared with before ruxolitinib (37% vs. 56%; relative risk [RR], 0.66; 95% confidence interval [CI], 0.52-0.84; P < .001). Phlebotomy requirements were similarly decreased in patients who had received at least 3 phlebotomies prior to ruxolitinib initiation (28% vs. 17%; RR, 1.65; 95% CI, 1.13-2.40; P < .01). Resolution of palpable splenomegaly was also documented (48% vs. 20%; RR, 2.45; 95% CI, 1.70-3.53; P < .0001). A total of 9.5% of patients discontinued ruxolitinib owing to treatment-emergent adverse events, and 81.7% of patients were receiving ruxolitinib at last known follow-up. CONCLUSION: These real-world results are similar to those reported from the RESPONSE trial, although additional follow-up is necessary to assess long-term outcomes and potential for late-onset toxicity.
INTRODUCTION: Ruxolitinib is approved for the treatment of polycythemia vera (PV) with hydroxyurea resistance or intolerance. Approval was based on the phase III RESPONSE trial, which demonstrated efficacy in a highly selected patient population. MATERIALS AND METHODS: To characterize the tolerability and outcomes of ruxolitinib outside of a clinical trial, we performed a multi-center retrospective analysis of patients with PV treated with ruxolitinib at 11 participating sites across the United States. Outcomes of interest included change in phlebotomy requirements after starting ruxolitinib and spleen response, as these were included in the primary composite outcome in the RESPONSE trial. RESULTS: One hundred twenty-six patients met eligibility criteria, and the median duration of follow-up was 22.4 months (range, 0-63.0 months). At 32 weeks after starting ruxolitinib, the percentage of patients who received at least 1 phlebotomy was significantly decreased compared with before ruxolitinib (37% vs. 56%; relative risk [RR], 0.66; 95% confidence interval [CI], 0.52-0.84; P < .001). Phlebotomy requirements were similarly decreased in patients who had received at least 3 phlebotomies prior to ruxolitinib initiation (28% vs. 17%; RR, 1.65; 95% CI, 1.13-2.40; P < .01). Resolution of palpable splenomegaly was also documented (48% vs. 20%; RR, 2.45; 95% CI, 1.70-3.53; P < .0001). A total of 9.5% of patients discontinued ruxolitinib owing to treatment-emergent adverse events, and 81.7% of patients were receiving ruxolitinib at last known follow-up. CONCLUSION: These real-world results are similar to those reported from the RESPONSE trial, although additional follow-up is necessary to assess long-term outcomes and potential for late-onset toxicity.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Alberto Alvarez-Larrán; Luz Martínez-Avilés; Juan Carlos Hernández-Boluda; Francisca Ferrer-Marín; María Luisa Antelo; Carmen Burgaleta; M Isabel Mata; Blanca Xicoy; Alejandra Martínez-Trillos; M Teresa Gómez-Casares; M Antonia Durán; Bárbara Marcote; Agueda Ancochea; Alicia Senín; Anna Angona; Montse Gómez; Vicente Vicente; Francisco Cervantes; Beatriz Bellosillo; Carles Besses Journal: Ann Hematol Date: 2014-07-02 Impact factor: 3.673
Authors: A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui Journal: Leukemia Date: 2013-06-06 Impact factor: 11.528
Authors: Alberto Alvarez-Larrán; Marta Garrote; Francisca Ferrer-Marín; Manuel Pérez-Encinas; M Isabel Mata-Vazquez; Beatriz Bellosillo; Eduardo Arellano-Rodrigo; Montse Gómez; Regina García; Valentín García-Gutiérrez; Mercedes Gasior; Beatriz Cuevas; Anna Angona; María Teresa Gómez-Casares; Clara M Martínez; Elena Magro; Rosa Ayala; Rafael Del Orbe-Barreto; Raúl Pérez-López; Maria Laura Fox; José-María Raya; Lucía Guerrero; Carmen García-Hernández; Gonzalo Caballero; Ilda Murillo; Blanca Xicoy; M José Ramírez; Gonzalo Carreño-Tarragona; Juan Carlos Hernández-Boluda; Arturo Pereira Journal: Cancer Date: 2022-04-13 Impact factor: 6.921